Paper
0
Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
Authors
Ted Getz,Tariq Kewan
Jan Bewersdorf,Jessica Stempel,Luca Lanino,Wei Wei,Najla Ali,Amy DeZern,Mikkael Sekeres,Geoffrey Uy,Hetty Carraway,Pinkal Desai,Elizabeth Griffiths,Eytan Stein,A. Brunner,Christine McMahon,Rory Shallis,Joshua Zeidner,Michael Savona,Somedeb Ball,Namrata Chandhok,Constantine Logothetis,Aram Bidikian,Gail Roboz,Benjamin Rolles,Eunice Wang,Amyah Harris,Maria Amaya,Hayley Hawkins,Justin Grenet,Zhuoer Xie,Yazan Madanat,Yasmin Abaza,Talha Badar,Torsten Haferlach,Jaroslaw Maciejewski,David Sallman,Anoop Enjeti,Kamal Al-Rabi,Khalid Halahleh,Devendra Hiwase,María Díez‐Campelo,David Valcárcel,Claudia Haferlach,Lisa Pleyer,Ιoannis Kotsianidis,Vasiliki Pappa,Valeria Santini,Angela Consagra,Aref Al‐Kali,Seishi Ogawa,Yasuhito Nannya,Maximilian Stahl,Matteo Porta,Rami Komrokji,Amer Zeidan,M.F. Amaya,María Diez-Campelo
+56 authors
,Vassiliki PappaJournal
Published
Nov 5, 2024
Show more
Save
Tip0
TipSave